Antiepileptic Drugs

I will need to take extra care of my teeth and gums while on this medication. This statement indicates the patient understands the importance of oral hygiene, as phenytoin can cause gingival hyperplasia, necessitating diligent dental care to prevent complications. B: I can go out for a beer while on this medication. Alcohol can interact negatively with phenytoin, potentially leading to increased side effects or reduced effectiveness of the medication. C: I can skip doses if the side effects bother me. Skipping doses can lead to inadequate seizure control and increased risk of seizures, undermining the purpose of the medication. D: I will be able to stop taking this drug once the seizures stop. Phenytoin requires careful management, and discontinuation should only occur under medical supervision to avoid seizure recurrence.

D: Take the drug at the same time every day. Consistent timing enhances therapeutic effectiveness and maintains stable drug levels in the bloodstream, which is crucial for controlling seizures in patients on antiepileptic medications. A: Driving is allowed after 2 weeks of therapy. Seizure control varies among individuals; many require a longer period without seizures before resuming driving safely, often needing medical evaluation. B: If seizures recur, take a double dose of the medication. Doubling the dose can lead to increased side effects or toxicity and is not a recommended response to breakthrough seizures. C: Antacids can be taken with the AED to reduce gastrointestinal adverse effects. Certain antacids can interfere with the absorption of AEDs, potentially reducing their effectiveness and compromising seizure control.

C: Contact the prescriber for another dosage form of the medication. In patients who are NPO, it is crucial to consult the prescriber to explore alternative routes for administering phenytoin, ensuring effective seizure management without compromising the patient's safety during surgery. A: Give the same dose intravenously. This choice overlooks the requirement for prescriber authorization and may not be appropriate without considering the patient's specific needs and the potential for adverse effects. B: Give the morning dose with a small sip of water. Administering oral medication contradicts the NPO directive, posing risks of aspiration and ineffective absorption, particularly in the context of surgery. D: Notify the operating room that the medication has been withheld. While communication is important, merely withholding the medication without consulting the prescriber fails to address the ongoing management of the patient's seizure disorder effectively.

The drug levels for carbamazepine are lower than expected. This indicates that autoinduction has begun, as carbamazepine enhances its own metabolism over time, leading to decreased plasma concentrations and a need for dosage adjustments. A: The drug levels for carbamazepine are higher than expected. Elevated levels suggest reduced metabolism, which contradicts the autoinduction process typically seen after prolonged use. C: The patient is experiencing fewer seizures. Fewer seizures may indicate effective therapeutic levels; however, this does not specifically demonstrate the onset of autoinduction regarding drug metabolism. D: The patient is experiencing toxic effects from the drug. Toxic effects suggest excessive levels or sensitivity, not the characteristic outcome of autoinduction, which usually results in lower drug levels over time.

B: Mix the drug with normal saline, and give it as a slow IV push. Administering phenytoin with normal saline ensures appropriate solubility and reduces the risk of precipitation, which is crucial for safe intravenous delivery and effective therapeutic outcomes. The slow IV push method helps to prevent adverse reactions associated with rapid administration. A: Give the dose as a fast intravenous (IV) bolus. Rapid administration of phenytoin can lead to severe complications, including hypotension and cardiac arrhythmias, which are not acceptable practices in patient care. C: Mix the drug with dextrose (D5W), and give it as a slow IV push. Phenytoin is incompatible with dextrose solutions, leading to precipitation and ineffective treatment, highlighting the importance of using normal saline instead. D: Mix the drug with any available solution as long as the administration rate is correct. Not all solutions are compatible with phenytoin; improper mixing can cause serious complications, making this option unsafe and unreliable.

Increased risk of suicidal thoughts and behaviors. The FDA's warning highlights a significant correlation between antiepileptic drugs and heightened suicidal ideation, necessitating vigilant monitoring by healthcare professionals to ensure patient safety and appropriate intervention. B: Signs of bone marrow depression Antiepileptic drugs are not primarily associated with bone marrow suppression; this concern is more relevant to other medication classes, making it an unlikely monitoring focus. C: Indications of drug addiction and dependency Antiepileptic medications typically do not lead to addiction or dependency, as they are not classified as controlled substances, thus reducing the necessity for monitoring this issue. D: Increased risk of cardiovascular events, such as strokes Current research does not establish a direct link between antiepileptic drugs and elevated cardiovascular event risks, indicating that this should not be a primary monitoring concern.

Diazepam is the drug of choice for the treatment of status epilepticus. This benzodiazepine acts rapidly to enhance the inhibitory effects of GABA, effectively terminating seizures and providing quick relief for patients in acute distress. B: Midazolam Although effective, midazolam is primarily used in non-emergency settings or for sedation, rather than as the first-line treatment for acute status epilepticus. C: Valproic acid Valproic acid is typically utilized for long-term management of seizures, rather than for the immediate and urgent treatment required in status epilepticus cases. D: Carbamazepine This antiepileptic medication is aimed at chronic seizure control and does not provide the rapid intervention necessary for effectively managing status epilepticus.

The safe and the toxic plasma levels of the drug are very close to each other. This characteristic of phenytoin's narrow therapeutic index signifies that the margin between effective and harmful concentrations is minimal, necessitating careful monitoring to prevent toxicity while ensuring therapeutic efficacy. Such precision is crucial in managing dosing and avoiding adverse effects in patients taking this medication. B: The phenytoin has a low chance of being effective. A narrow therapeutic index does not imply low effectiveness; it indicates a delicate balance between efficacy and toxicity, requiring meticulous dosage management. C: There is no difference between safe and toxic plasma levels. The narrow therapeutic index explicitly defines a significant distinction between safe and toxic levels, emphasizing the need for careful monitoring of drug concentrations. D: A very small dosage can result in the desired therapeutic effect. While dosage precision is critical, a narrow therapeutic index means small changes can lead to toxicity, not necessarily guaranteeing therapeutic effects from minimal dosing.

Stopping this medication abruptly may cause withdrawal seizures. A refill is needed right away. Discontinuing an antiepileptic drug suddenly can lead to serious complications, including the risk of seizures. The patient has been on this treatment for an extended period, making it crucial to maintain consistent medication levels to prevent adverse effects. Immediate action is necessary to ensure the patient's safety and health. A: He is taking another antiepileptic drug, so he can go without the medication for a week. Relying solely on another medication without proper guidance can lead to inadequate seizure control and potential harm. C: He can temporarily increase the dosage of his other antiseizure medications until you get the refill. Adjusting dosages without a healthcare provider's approval may result in toxicity or suboptimal therapeutic effects. D: He can stop all medications because he has been treated for several years now. Long-term treatment does not equate to safety in discontinuation; abrupt cessation poses significant risks for seizure recurrence.

The patient's seizures should be under control because this is a therapeutic drug level. A phenytoin level of 18 mg/mL falls within the typical therapeutic range, indicating effective management of seizure activity. A: The patient is at risk for seizures because the drug level is not at a therapeutic level. A level of 18 mg/mL is indeed therapeutic, hence not posing a seizure risk. C: The patient's seizures should be under control if she is also taking a second antiepileptic drug. While additional medications may aid control, the current phenytoin level is sufficient on its own. D: The drug level is at a toxic level, and the dosage needs to be reduced. A phenytoin level of 18 mg/mL is not considered toxic, therefore, no dosage adjustment is necessary.

Gabapentin is prescribed primarily for the management of neuropathic pain, which is a common condition that may not necessarily involve seizures. Its effectiveness in alleviating nerve-related discomfort justifies its use in patients without a seizure history. B: The medication is helpful for the treatment of multiple sclerosis. Gabapentin is not specifically indicated for multiple sclerosis; it primarily targets neuropathic pain rather than autoimmune conditions. C: The medication is used to reduce the symptoms of Parkinson's disease. Gabapentin does not address the core symptoms of Parkinson's disease, focusing instead on nerve pain relief and other conditions. D: The medical record is missing the correct information about the patient's history of seizures. Assuming an omitted seizure history lacks evidence, and gabapentin's primary indication lies in neuropathic pain treatment.

AED therapy is usually lifelong. Chronic management is essential due to the persistent nature of epilepsy, with many patients requiring long-term treatment to prevent seizure recurrence and maintain optimal control over their condition. A: AED therapy can be stopped when seizures are stopped. Discontinuing AEDs after seizure resolution may lead to relapse, as underlying issues causing seizures often persist without medication. D: A dose may be skipped if the patient is experiencing adverse effects. Skipping doses can diminish therapeutic effectiveness, potentially resulting in uncontrolled seizures and worsening the patient's overall condition.

10 mL To administer 200 mg of carbamazepine, the nurse calculates the required volume using the provided concentration of 100 mg per 5 mL. This results in a dosage of 10 mL per dose, ensuring the child receives the correct medication amount. A: 5 mL The volume of 5 mL only delivers 100 mg, which is insufficient for the 200 mg required dosage. B: 15 mL Administering 15 mL would provide 300 mg, exceeding the prescribed dose and potentially causing adverse effects. C: 20 mL A dosage of 20 mL equates to 400 mg, which is not appropriate for the child's treatment plan.